HTWR's Continued Stock Slide May Be Due To Aspirin Requirements Causing Bleedin
I'm beginning to view the HTWR slide to Friday's BELOW $70 as being caused by their Aspirin Dose requirements of 160 mg to 325 mg DAILY. Remember that this is ABOVE the AHA/ACC safety statement.
A possible large number of bleeding events at multiple physiological sites being reported may be the reason. Just speculating due to the large number of peer-reviewed medical papers that I previously posted that warned of a daily aspirin requirement. Remember, the vast majority of those papers were concerned with a baby aspirin. Therefore, the HVAD requirement of a multiple strength of a baby aspirin could be considered even more dangerous, especially for DT and TRANSPLANT ELIGIBLE patients.
If HTWR's stock continues to slide, I would speculate that the probability of significant bleeding episodes over multiple sites has increased as the reason. Meanwhile HTWR has not announced the publication of important medical papers going forward. I take that as further evidence to consider. It's not only what a CEO states that should be considered, but also what is not discussed. Remember that the FDA has an Aspirin warning on its site. The warning, among other discussed Aspirin issues, clearly states that Aspirin dose counts. The stronger the dose the higher the risk for an adverse significant bleeding event.